Prof Caroline Dive discusses immunotherapy on BBC Breakfast

Описание: Professor Caroline Dive, Interim Director of the Cancer Research UK Manchester Institute, and Director of the National Biomarker Centre, was invited onto BBC Breakfast in Salford to discuss the launch of a multi-million-pound UK-wide platform into cancer immunotherapy.

00:00 What is Immunotherapy?
00:31 Immunotherapy saved Alex's life
00:53 "I'm completely clear that immunotherapy saved my life"
01:23 A new study to improve immunotherapy
01:56 "We want to do better by cancer patients" Prof Samra Turailic
02:47 "We're joined on the sofa by Professor Caroline Dive"
04:00 "Look for the molecules"
05:15 The Goal: To give the right immunotherapy, to the right patient, at the right time
06:50 Not a competition, but a global collaboration
07:40 Avenues for new immunotherapies

The new UK-wide programme, titled MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity), has been set up to evaluate the many barriers to the success of immunotherapy.

Drugs that help the immune system fight cancer, collectively known as immunotherapy, are a frontline treatment for some types of cancer like melanoma (a form of skin cancer). Long-term studies have shown that it can completely eradicate advanced disease for some patients.

But the majority of people with cancer do not benefit, with many relapsing or experiencing significant side effects. Even in melanoma, where immunotherapy is most successful, only 50% respond.

MANIFEST will aim to validate which biomarkers are present in patients before they start immunotherapy, and to develop tests that can monitor them during treatment. The initial testing will include 3000 patients who have already completed their treatment and then 3000 who are starting treatment across the UK for breast, bladder, kidney and skin cancer, with plans to include additional cancer types as the programme expands.

Over four years, data will be collected from these patients, using procedures like blood tests, stool samples and tissue biopsies. The team will analyse different aspects of cancerous tumours, including their genetic makeup,
where they are in relation to immune cells, and what chemical signals they are producing. They will also generate a profile of immune cells in each patient’s bloodstream and analyse their gut microbiome.

For further information on MANIFEST, visit www.manifestio.org.uk.

To find out more about the work of the Cancer Research UK Manchester Institute, visit our website: https://www.cruk.manchester.ac.uk/

For more on the research happening the Cancer Research UK National Biomarker Centre, go to https://cruknbc.org/